Final Programme www.ilca2020.org - ILCA 2020
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Programm Final Programme www.ilca2020.org
Table of Contents
Letter of Welcome ............................................................................................. 3
Programme at a Glance..................................................................................... 4
On demand Sessions from 7 September ........................................ 4
Friday, 11 September 2020 .............................................................. 6
Saturday, 12 September 2020 .........................................................9
Sunday, 13 September 2020 ............................................................ 12
Practicalities ....................................................................................................... 14
Sponsors, Media and other Partners ............................................................. 15
Partner Symposia............................................................................................... 16
2 I ILCA VIRTUAL CONFERENCE 2020
Weclome
Letter of Welcome
Dear ILCA members, colleagues, and friends,
It is our great pleasure to invite you to attend the Virtual 14th Annual Conference of the
International Liver Cancer Association (ILCA) from 11 to 13 September 2020.
Our community will gather for three days of sharing knowledge, of scientific learning and
intensive networking around the latest advances in liver cancer research, basic translational
and clinical research.
ILCA continues to develop new programmes and initiatives and will again bring together
the most eminent liver cancer experts from around the globe with the goal of improving the
prevention, diagnosis, treatment and care of patients.
The programme that the Governing Board has put together will provide you with an
outstanding educational experience. We have developed a range of new session formats
with exciting content to encourage knowledge sharing between physicians, researchers,
young investigators and partners from all over the world.
We look forward to welcoming you all virtually as we work together to advance liver cancer
science and care to offer true hope to patients.
Warm regards,
On behalf of the ILCA Governing Board
Bruno Sangro, MD, PhD Augusto Villanueva, MD, PhD
ILCA President ILCA Executive Secretary
3 I ILCA VIRTUAL CONFERENCE 2020
Glance
Programme at a Glance
ON DEMAND SYMPOSIA
SEQUENCING AND STRATIFICATION OF SYSTEMIC THERAPY IN HCC SYMPOSIUM
CHAIRS: LORENZA RIMASSA, MD (ITALY), R. KATE KELLEY, MD (USA)
The Growing Landscape of Systemic Therapies for Advanced HCC
• A New Choice: Selecting Among Evidence-Based 1st Line Therapies for Advanced HCC
Ann-Lii Cheng, MD, PhD (USA)
• The Second Line in a Dynamic Landscape
Stephen Chan, MD, PhD (Hong Kong)
• The evolving role of checkpoint inhibitors in advanced HCC
Anthony El-Khoueiry Chan, MD (USA)
Expanding the Reach of Systemic Therapy in HCC
• Novel Molecular Targets, Agents and Biomarkers for HCC
Josep Maria Llovet, MD, PhD (Spain/USA)
Endpoints for Systemic Therapy Trials in Advanced HCC: Should Overall Survival be the Only Gold
Standard in Expanding Treatment Landscape?
• PRO: OS remains gold standard.
Maria Reig, MD, PhD (Spain)
• CON: Surrogate endpoints are acceptable and necessary.
Richard Finn, MD (USA)
Systemic Therapy in Special Populations
• Hepatic dysfunction (Child Pugh >A) and Post-transplant
Laura Kulik, MD (USA)
• HIV, dialysis, and autoimmune disease
David Pinato MD, MRCP (UK)
• Mixed HCC-cholangiocarcinoma
Gregory Gores MD, (USA)
Immunotherapy in Earlier Stages of HCC
• HCC Immunotherapy in Earlier Stages of HCC
Bruno Sangro, MD, PhD (Spain)
SYMPOSIUM: CANCER CARE BEYOND ANTI-TUMOR THERAPY
CHAIR: BRUNO SANGRO, MD, PHD (SPAIN)
Pshychooncology: Basic Principles applied to liver cancer
Maria DieTrill, PhD (Spain)
Management of cancer-treatment related Fatigue and cancer-related cachexia:
Combine supportive, palliative, and rehabilitative care
Florian Strasser, MD (Switzerland)
4 I ILCA VIRTUAL CONFERENCE 2020
Glance
Programme at a Glance
ON DEMAND SYMPOSIA
ILCA GUIDANCE SYMPOSIUM: SYSTEMIC THERAPY GUIDANCE AND BIOMARKER
DEVELOPMENT IN HCC
Systemic Therapy Guidance Biomarker Development in HCC Guidance
Tim Meyer, MD, PhD (UK) Augusto Villanueva, MD, PhD (USA)
R. Kate Kelley, MD (USA) Amit Singal, MD (USA)
SINGLE TOPIC WORKSHOP: MOLECULAR DIVERSITY AND SYSTEMIC TREATMENT FOR
HCC AND SURGERY IN THE MANAGEMENT OF HCC: ROLE OF SURGEONS AND OF THE
RADIOLOGISTS
CHAIR : JEAN-CLAUDE NAULT, MD, PHD (FRANCE)
molecular diversity and systemic treatment Surgery in the management of HCC: role of
for HCC surgeons and the radiologists
Amaia Lujambio, PhD (USA) Riccardo Lencioni, MD (Italy)
Andrew Zhu, MD, PhD (USA) Eric Vibert, MD, PhD (France)
BASIC SCIENCE SYMPOSIUM: MOLECULAR PATHOGENESIS AND TARGETS IN
CHOLANGIOCARCINOMA
CHAIR: AUGUSTO VILLANUEVA, MD, PHD (USA)
Pathogenesis and molecular drivers of cholangiocarcinoma
Gregory Gores, MD (USA)
Novel therapeutic targets in cholangiocarcinoma: Beyond IDH
Daniela Sia, PhD (USA)
Biomarkers in cholangiocarcinoma
Jesper B. Andersen, MD, PhD (Denmark)
5 I ILCA VIRTUAL CONFERENCE 2020
Glance
Programme at a Glance
FRIDAY, 11TH SEPTEMBER 2020
CEST TIME
15.00 - 16.00 YOUNG INVESTIGATOR SESSION
Chair: Morris Sherman, MD, PhD (Canada)
4 oral presentations submitted by young reserachers followed by Q&A time.
• O
-01 International, Multicenter Study on The Outcome of Locoregional Therapy Before
Liver Transplant for Hepatocellular Carcinoma Extending the Milan Criteria
Helena Degroote (Belgium)
• O-02 Impact of Age on Sorafenib Outcomes in Hepatocellular Carcinoma: An
International Cohort Study.
Saur Hajiev (UK)
• O-03 Prospective Intra-Individual Comparison of Contrast-Enhanced Ultrasound with
Sulfur Hexafluoride and Perfluorobutane For Diagnosis of Hepatocellular Carcinoma in
High-Risk Patients
Hyo-Jin Kang (Republic of Korea)
• O-04 Cabozantinib Enhances the Efficacy and Immune Activity of Anti-Pd1 Therapy in A
Murine Model of Hepatocellular Carcinoma
Catherine Willoughby (Spain)
16.05 - 16.35 BEST CLINICAL POSTER SESSION
10 Top scored clinical e-Posters presenters will participate on this LIVE Q&A session
where participants and specialists will ask poster presenters about findings described
in their poster.
Chair: Laura Kulik, MD (USA)
• P-47: Benefits and Harms of Hepatocellular Carcinoma Surveillance in A Prospective
Cohort of Patients with Cirrhosis
Amit G. Singal (USA)
• P-40: A Fucosylated Kininogen-Based Biomarker Panel Is Highly Accurate for Early
Detection Hepatocellular Carcinoma in Patients with Cirrhosis: A Phase Iii Biomarker
Evaluation
Anand Mehta (USA)
• P
-103: Exposure-Response Analysis for Nivolumab + Ipilimumab Combination Therapy
in Patients with Advanced Hepatocellular Carcinoma
Bruno Sangro (Spain)
•
P-32: Standardized Sampling and Reporting Protocol Is the Key to Improve
Microvascular Invasion Detection Rate
Lijuan Liu (China)
6 I ILCA VIRTUAL CONFERENCE 2020
Glance
Programme at a Glance
FRIDAY, 11TH SEPTEMBER 2020
CEST TIME
16.05 - 16.35 • P
-66: Overall Survival Is Impacted by Liver Failure and Co-Morbidities Rather Than
Etiology Of Cirrhosis in Patients with Hepatocellular Carcinoma Detected During A
Surveillance Program
Nathalie Ganne-Carrie (France)
• P
-109: Post-Registration Experience of Nivolumab Therapy in Patients with Advanced
Hepatocellular Carcinoma (Hcc): An International Study.
Petros Fessas (UK)
•
P-115: Sequential Treatment with Sorafenib Followed by Regorafenib In Patients with
Unresectable Hepatocellular Carcinoma (HCC): Interim Analysis of The Observational
REFINE Study
Philippe Merle (France)
• P-03: Ramucirumab For Patients with Advanced Hepatocellular Carcinoma and
Elevated Alpha Fetoprotein Following A Non-Sorafenib Based Systemic Therapy:
Interim Results from An Expansion Cohort of The Phase 3 Reach-2 Study
Richard Finn (USA)
• P
-56: Abnormal and Euthyroid Ranges of Thyroid Hormones in Serum and Liver Cancer
Mortality: A Cohort Study
Won Sohn (Republic of Korea)
17.45 - 18.15 BEST BASIC / TRANSLATIONAL POSTER SESSION
10 Top scored clinical e-Posters presenters will participate on this LIVE Q&A session
where participants and specialists will ask poster presenters about findings described
in their poster
Chair: Amaia Lujambio, PhD (USA))
•
P-92: Characterization of Chromatin Accessibility in Hepatocellular Carcinoma Cells
Using Single Cell Atac Sequencing
Amanda Craig (USA)
•
P-81: Cold-Inducible Rna Binding Protein as A Vaccination Platform Against
Hepatocellular Carcinoma
David Repáraz (Spain)
•
P-91: Dual Targeting of Tumor Associated Macrophages and Immunosuppressive
Granulocytic Myeloid-Derived Suppressor Cells Augments Pd-1 Blockade in
Cholangiocarcinoma
Emilien Loeuillard (USA)
7 I ILCA VIRTUAL CONFERENCE 2020
Glance
Programme at a Glance
FRIDAY, 11TH SEPTEMBER 2020
CEST TIME
17.45 - 18.15 •
P-77: Identification of Neoantigen-Reactive Tumor-Infiltrating T Cell in Hepatocellular
Carcinoma.
Enric Vercher Herraez (Spain)
•
P-86: Activated Peripheral Blood Lypmphocytes Of Hepatocellular Carcinoma Patients
(Hcc) Are Associated with Increased Risk of Early Dermatologic Adverse Effects During
Sorafenib Treatment
Josep Corominas Argente del Castillo (Spain)
•
P-76: Immune-Remodeling Effects of Lenvatinib Plus Anti-Pd1 In A Murine Model of
Hepatocellular Carcinoma
Laura Torrens (Spain)
•
P-70: Immunogenomic Characterization of Multifocal Liver Cancer
Liangqing Dong (China)
•
P-90: Implications of Notch3 Expression and Signaling For Cholangiocarcinogenesis
Sarah Fritzsche (Germany)
•
P-28: Purification and Digital Scoring of Extracellular Vesicles for Detection of Early-
Stage Hepatocellular Carcinoma
Vatche Agopian (USA)
19.20 - 19.40 ILCA Junior Investigator Awards Ceremony
Chairs: ILCA President
Bruno Sangro, MD, PhD (Spain)
ILCA Executive Secretary
Augusto Villanueva, MD, PhD (USA)
ILCA Treausurer
Sandrine Faivre, MD, PhD (France)
ILCA Past President
Morris Sherman, MD, PhD (Canada)
8 I ILCA VIRTUAL CONFERENCE 2020
Glance
Programme at a Glance
SATURDAY, 12TH SEPTEMBER 2020
CEST TIME
13.40 – 14.00 HIGHLIGHTS OF THE DAY 1
A summary conversation capturing the first day programme of presentations, panel
discussions and the interactive dialogue at the conference day.
Augusto Villanueva, MD, Phd (USA)
Laura Kulik, MD (USA)
GENERAL SESSION 1: MOLECULAR PATHOGENESIS, CELL BIOLOGY AND
15.00 - 16.00
TRANSLATIONAL RESEARCH - Q&A
Chair: Jean Charles Nault, MD, PhD (France)
• O-05: Lysyl Oxidase Shapes Physical and Metabolic Interactions Between Tumor And
Stroma in Cholangiocarcinoma Patients
Monika Lewinska (Denmark)
• O-06: Supervised Learning Based on Tumor Imaging and Biopsy-Derived Transcriptomic
Data Predicts Response of Hepatocellular Carcinoma to Transarterial
Geoffrey Fucile (Switzerland)
• O-07: Telomere Length Is A Major Determinant of Hepatocellular Carcinoma Diversity
and A Therapeutic Target
Massih Ningarhari (France)
• O-08: Cooperation Between Distinct Cancer Driver Genes Underlies Inter-Tumor
Heterogeneity in Hepatocellular Carcinoma
Amaia Lujambio (USA)
Q&A BASIC SCIENCE SYMPOSIUM: MOLECULAR PATHOGENESIS AND TARGETS
16.05 - 16.20
IN CHOLANGIOCARCINOMA
15 minutes Q&A with the speakers and moderator. Participants will be able to ask questions
in writing using the Q&A box.
Chair: Augusto Villanueva, MD, PhD (USA)
• Pathogenesis and molecular drivers of cholangiocarcinoma
Gregory Gores, MD (USA)
• Novel therapeutic targets in cholangiocarcinoma: Beyond IDH
Daniela Sia, PhD (USA)
• Biomarkers in cholangiocarcinoma
Jesper B. Andersen, MD, PhD (Denmark)
9 I ILCA VIRTUAL CONFERENCE 2020
Glance
Programme at a Glance
SATURDAY, 12TH SEPTEMBER 2020
CEST TIME
Q&A SEQUENCING AND STRATIFICATION OF SYSTEMIC THERAPY IN HCC
16.20 - 16.35
SYMPOSIUM
15 minutes Q&A with the speakers and moderator. Participants will be able to ask questions
in writing using the Q&A box.
Chairs: Lorenza Rimassa, MD (Italy), R. Kate Kelley, MD (USA)
• The Growing Landscape of Systemic Therapies for Advanced HCC
- The Second Line in a Dynamic Landscape
Stephen Chan (Honk Kong)
• Expanding the Reach of Systemic Therapy in HCC
- Novel Molecular Targets, Agents and Biomarkers for HCC
Josep Maria Llovet (Spain/USA)
• E
ndpoints for Systemic Therapy Trials in Advanced HCC:
Should Overall Survival be the Only Gold Standard in Expanding Treatment Landscape?
- PRO: OS remains gold standard.
Maria Reig (Spain)
- CON: Surrogate endpoints are acceptable and necessary.
Richard Finn (USA)
• Systemic Therapy in Special Populations
- HIV, dialysis, and autoimmune disease
David Pinato (UK)
SINGLE TOPIC WORKSHOP Q&A ON "MOLECULAR DIVERSITY AND SYSTEMIC
16.40 - 16.55 TREATMENT FOR HCC" AND "SURGERY IN THE MANAGEMENT OF HCC: ROLE OF
SURGEONS AND OF THE RADIOLOGISTS"
15 minutes Q&A session with the speakers of the Single Topic Workshop and moderator.
Participants will be able to ask questions in writing using the Q&A box. .
Chair : Jean-Claude Nault, MD, PhD (France)
• Molecular diversity and systemic treatment for HCC
Amaia Lujambio, PhD (USA)
Andrew Zhu, MD, PhD (USA)
• Surgery in the management of HCC: role of surgeons and the radiologists
Riccardo Lencioni, MD (Italy)
Eric Vibert, MD, PhD (France)
10 I ILCA VIRTUAL CONFERENCE 2020Glance
Programme at a Glance
SATURDAY, 12TH SEPTEMBER 2020
CEST TIME
16.55 - 17.10 Q&A FOR ILCA SYMPOSIUM: CANCER CARE BEYOND ANTI-TUMOR THERAPY
15 minutes Q&A sessions with 2 speakers and moderator. Participants will be able to ask
questions through the Q&A box..
Chair: Bruno Sangro, MD, PhD (Spain)
• Pshychooncology: Basic Principles applied to liver cancer
Maria DieTrill, PhD (Spain)
• Management of cancer-treatment related Fatigue and cancer-related cachexia:
Combine supportive, palliative, and rehabilitative care
Florian Strasser, MD (Switzerland)
17.15 - 18.45 GENERAL SESSION 2: EPIDEMIOLOGY, STAGING AND PROGNOSIS
Chair: Sasan Roayaie, MD, FACS. (USA)
O-09: Prognostic Role of Pecs2 Index in Advanced Biliary Tract Cancer Patients Treated
•
with First Line Chemotherapy: Training and Validation Cohorts.
Giulia Rovesti (Italy)
O-10: Early Recurrence of Hepatocellular Carcinoma Following Transplantation: Risk
•
Score from A Multi-Institutional Study Of > 3000 Patients
Parissa Tabrizian (USA)
O-12: The Metroticket 2.0 And Afp Score Have Similar Performance to Predict Post-Lt
•
Outcomes: Results of A Multinational Multicentre Cohort Study.
Federico Piñero (Argentina)
O-13: Patient-Reported Barriers Are Associated with Hcc Surveillance Receipt in A
•
Multi-Center Cohort of Patients with Cirrhosis
Amit G. Singal (USA)
O-14: Is Repeat Resection for Recurrent Intrahepatic Cholangiocarcinoma Warranted?
•
Outcomes of An International Multicenter Analysis
Matthew Holzner (USA)
O-15: A Multicenter, Cross-Section Study of The Impact of Covid-19 Pandemic on The
•
Management of Hepatocellular Carcinoma A High-Prevalence French Area.
Giuliana Amaddeo (France)
11 I ILCA VIRTUAL CONFERENCE 2020Glance
Programme at a Glance
SUNDAY, 13TH SEPTEMBER 2020
CEST TIME
13.40 – 14.00 HIGHLIGHTS OF THE DAY 2
A summary conversation capturing the first day programme of presentations, panel
discussions and the interactive dialogue at the conference day.
Amaia Lujambio, PhD (USA)
Augusto Villanueva, MD, PhD (USA)
15.00 - 16.30 GENERAL SESSION 3: DIAGNOSIS, IMAGING AND BIOMARKERS
Chair: Amit Singal, MD (USA)
• O-16: Construction and Implementation of An Artificial Intelligence Model for
Microvascular Invasion Prediction of Hepatocellular Carcinoma
Han Xiao (China)
• O-17: Comparative Accuracy of Abbreviated Mri Vs. Ultrasound for Detection of Early-
Stage Hcc In Patients with Cirrhosis
Takeshi Yokoo (USA)
• 0-18: Alpha-Fetoprotein (AFP) Kinetics as A Potential Surrogate Biomarker in Patients
(Pts) With Hepatocellular Carcinoma (HCC) Treated with Atezolizumab (Atezo) +
Bevacizumab (Bev)
Andrew X. Zhu (USA)
• O-19: Unannotated Small RNA In Circulating Extracellular Vesicles Detect Early Stage
Liver Cancer
Johann von Felden (Germany)
• O-20: Improved Sensitivity for Early-Stage Hepatocellular Carcinoma Detection with A
Novel Blood-Based Panel of Methylated Dna And Protein Markers
Amit Singal (USA)
• O-21: Inflammatory and Insulinemic Potential of Diet And Lifestyle With Risk Of
Hepatocellular Carcinoma
Xuehong Zhang (USA)
16.35 - 16.50 Q&A ILCA SYSTEMIC THERAPY GUIDANCE
15 minutes Q&A with speakers and moderator. Participants will be able to ask questions in
writing using a Q&A chat box.
Tim Meyer, MD, PhD (UK)
R. Kate Kelley, MD (USA)
12 I ILCA VIRTUAL CONFERENCE 2020Glance
Programme at a Glance
SUNDAY, 13TH SEPTEMBER 2020
CEST TIME
16.50 - 17.05 Q&A ILCA BIOMARKER DEVELOPMENT IN HCC GUIDANCE
15 minutes Q&A with speakers and moderator. Participants will be able to ask questions in
writing using a Q&A chat box.
Augusto Villanueva, MD, PhD (USA)
Amit Singal, MD (USA)
17.10 - 18.40 GENERAL SESSION 4: THERAPY AND CLINICAL TRIALS
Chair: Tim Meyer, MD, PhD (UK)
• O-22: The Novel Regimen of Tremelimumab In Combination with Durvalumab Provides
a Favorable Safety Profile and Clinical Activity for Patients with Advanced
R. Katie Kelley (USA)
• O-23: Transarterial Chemoembolization and Radioembolization Are Similarly Effective
in Achieving Successful Hepatocellular Carcinoma Downstaging In the Multicenter
Evaluation of Reduction in Tumor Size Before Liver Transplantation (Merits-Lt)
Consortium
Neil Mehta (USA)
• 0-24: Outcomes for Patients with Advanced Hepatocellular Carcinoma and Child-Pugh
B Liver Function in The Phase 3 Celestial Study of Cabozantinib Versus Placebo
Anthony B. El-Khoueiry (USA)
• 0-25: Radiological and Pathological Response to Neoadjuvant Nivolumab In Patients
with Bclc a Hcc Treated by Curative Percutaneous Irreversible Electroporation:
Preliminary Report from The French Multicentre Phase 2 Nivolep Trial.
Pierre Nahon (France)
• O-26: Proton Beam Radiotherapy Versus Radiofrequency Ablation Treatment in
Patients with Recurrent Hepatocellular Carcinoma: A Randomized Controlled Phase 3
Non-Inferiority Aproh Trial
Joong-Won Park (Republic of Korea)
• O:27: Nivolumab After Selective Internal Radiation Therapy (Sirt) Using Sir-Spheres
Resin Microspheres in Patients with Hepatocellular Carcinoma: The Nasir-Hcc Trial
Bruno Sangro (Spain)
18.40 - 18.50 FAREWELL ADDRESS
ILCA President, Bruno Sangro, MD, PhD (Spain)
13 I ILCA VIRTUAL CONFERENCE 2020Practicalities
Practicalities
ABOUT THE CONFERENCE
▶ About ILCA
The International Liver Cancer Association (ILCA) is the only international organisation devoted exclusively to
liver cancer research for experts from all related disciplines.
ILCA aims at creating an international multidisciplinary forum to address the increasing incidence of liver
cancer through the enhancement of the knowledge of clinical, translational, and basic research, ultimately
creating novel preventive, diagnostic and therapeutic strategies.
The purpose for which ILCA was established is the advancement of medical education, research, and clinical
care in the field of liver cancer.
Please come and visit us at the ILCA stand. The ILCA Team will be pleased to meet you and provide you with
any information you may wish to have on ILCA activities, membership, and future conferences.
Information is also available at
www.ilca-online.org Intern a tional Liver Cancer A s soci at io n
▶ Accreditation
The International Liver Cancer Association’s 14th Annual Conference being the first ILCA virtual conference
this year has been accredited by the European Accreditation Council for Continuing Medical Education
(EACCME®) with 7 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of
credit that he/she actually spent in the educational activity.
▶ Junior Investigator Awards
ILCA will recognise extraordinary achievements in liver cancer research across disciplines and support the
professional development of four junior investigators in training. The awards will be given for novel and
significant liver cancer research across the fields of basic cancer research; translational cancer research;
cancer diagnosis; the prevention of cancer; or cancer patients treatment.
The investigators who submit the best clinical oral and best poster presentations and the best basic-
translational oral and best poster presentations will be honoured LIVE on Friday, 11 September 2020 at
19:20 CEST.
▶ Official Language
The official language of the conference is English. Simultaneous translation will not be provided.
14 I ILCA VIRTUAL CONFERENCE 2020Sponsors, Media and other Partners
Partners
ILCA warmly thanks all the Partners and Supporters for their involvement in ILCA 2020.
Partners & Supporters
Principal Partners
Conference Partners
Supporters
15 I ILCA VIRTUAL CONFERENCE 2020Sponsors, Media and other Partners
Partners
Media Partners
Partner Societies
• American Association for the Study of Liver Diseases (AASDL)
• American Society of Clinical Oncology (ASCO)
• Asian Pacific Association for the Study of the Liver (APASL)
• Asia-Pacific Primary Liver Cancer Expert Association
• Canadian Association of Gastroenterology (CAG)
• Canadian Association for the Study of the Liver (CASL)
• European-African Hepato-Pancreato-Biliary Association (E-AHPBA)
• European Association for Cancer Research (EACR)
• European Association for the Study of the Liver (EASL)
• European Society for Medical Oncology (ESMO)
• European Society of Surgical Oncology (ESSO)
• International Liver Transplantation Society (ILTS)
• Japan Society of Clinical Oncology (JSCO)
• Japanese Society of Medical Oncology (JSMO)
• Korean Association for Clinical Oncology (KACO)
• Korean Association for the Study of the Liver (KASL)
• Korean Cancer Association (KCA)
• Korean Liver Cancer Association (KLCA)
• Korean Association of Hepato-Biliary-Pancreatic Surgery (KAHBPS)
• Society of Interventional Oncology (SIO)
• Stockholm Liver Week
• United European Gastroenterology (UEG)
16 I ILCA VIRTUAL CONFERENCE 2020ILCA
About ILCA
▶ Genesis
Liver cancer is rapidly increasing worldwide, triggering widespread interest and strong focus surrounding
all aspects of this disease. Given the naturally multidisciplinary nature of liver cancer, however, no single
association has before the International Liver Cancer Association (ILCA) adopted a transversal approach to
liver cancer by connecting expertise from interrelated fields, research, and treatment levels. In response
to this shortfall, ILCA was established in 2006 and is currently the only international organisation devoted
exclusively to liver cancer across disciplines.
▶ Our Mission
ILCA strives to advance research in the pathogenesis, prevention, and treatment of liver cancer, by promoting
novel pathogenic, diagnostic, and therapeutic interventions for liver cancer, and taking a transversal
approach to research. Indeed, ILCA brings together scientists, physicians and allied professionals from
all interrelated fields and countries and strives to welcome and incorporate individuals involved in all
the scientific disciplines devoted to basic, translational and clinical research in liver cancer as individual
members. ILCA actively partners with other professional associations involved in any aspect related to liver
cancer research, with the objective to join efforts for the benefit of science.
▶ Joining Our Community
We invite you to discover more about ILCA on www.ilca-online.org, as well as to connect with our expanding
group of interested physicians, scientists, and allied health professionals from various fields and from around
the world. Membership to ILCA not only provides you with exclusive benefits such as reduced registration
rates to our Annual Conferences, exciting networking and educational opportunities and active involvement
in association affairs; it also helps us to develop our activities and our reach to advance liver cancer research
and care.
▶ ILCA Governing Board
Executive Committee Council Contact us
President Joong-Won Park (Republic of Korea) Association (ILCA)
Bruno Sangro (Spain) Sasan Roayaie (USA) Boulevard du Souverain, 280
B-1160 Brussels – Belgium
Laura Kulik (USA)
Executive Secretary Tel:+32 (0)2 320 2531
Jeong Min Lee (Republic of Korea)
Augusto Villanueva (USA) info@ilca-online.org
Amit Singal (USA)
Treasurer Eric Vibert (France)
Sandrine Faivre (France) Tim Meyer (UK)
Amaia Lujambio (USA)
Past President Michiie Sakamoto (Japan)
Morris Sherman (Canada) Jean-Charles Nault (France)
R. Kate Kelley (USA)
17 I ILCA VIRTUAL CONFERENCE 2020Symposia
Partner Symposia
Partner Symposia at ILCA 2020 give you the chance to discuss and exchange knowledge on data and
products with our industry partners.
FRIDAY, 11TH SEPTEMBER 2020
14.00 - 15.00 ROCHE INDUSTRY PARTNER SYMPOSIUM
How could treatment practice change with cancer immunotherapy combinations in
patients with HCC?
In this symposium an esteemed panel will provide an overview of the evolving treatment
landscape for HCC, review the most recent data for cancer immunotherapy combinations in
patients with unresectable HCC and, crucially, provide expert insights and guidance on how
their safety profiles can be navigated.
• Navigating the shifting treatment patterns for HCC
• Understanding the latest efficacy data for unresectable HCC
• Discussing safety with cancer immunotherapy combinations
• Making the correct clinical decisions: what do we need to know?
• Reviewing a patient case: who are the right patients for cancer immunotherapy
combinations?
Speakers:
Peter Galle, University Medical Centre, Mainz, Germany
Riccardo Lencioni, Director of the Division of Diagnostic Imaging and Intervention in the
Department of Hepatology and Liver Transplantation Pisa University Hospital, Italy
Bruno Sangro, Director of the Liver Unit and Co-Director of the HPB Oncology Area Clínica
Universidad de Navarra
Jian Zhou, Zhongshan Hospital, China
This symposium is intended only for physicians practicing outside the USA!
16.40 - 17.40 IPSEN INDUSTRY PARTNER SYMPOSIUM
Changing the disease course in HCC, current evidence and future insights
This symposium will provide an update on the most recent data on HCC treatment, within the
context of the rapidly evolving treatment landscape. As well as discussing the latest clinical
data surrounding treatment sequencing to achieve optimal outcomes for patients.
Finally, looking to the future, how application of the latest preclinical and clinical data
may shape future treatment strategies, with an overview of combinations currently under
investigation, and implications for the future of HCC treatment.
• Translating latest clinical trials evidence into treatment decisions
• Sequencing of systemic therapy in today’s clinical practice
• Insights from the tumour microenvironment for the 2021 treatment landscape
18 I ILCA VIRTUAL CONFERENCE 2020Symposia
Partner Symposia
FRIDAY, 11TH SEPTEMBER 2020
16.40 - 17.40 IPSEN INDUSTRY PARTNER SYMPOSIUM Continued form page18
Speakers:
Sandrine Faivre, Professor Medical Oncology, Hôpital St-Louis, France
Josep Maria Llovet, Professor IDIBAPS-HOSPITAL CLÍNIC / ICAHN School of Medicine
Arndt Vogel, Professor for gastrointestinal oncology, Hannover Medical School
This is an educational, non-promotional meeting organised and funded by Ipsen. The opinion
and views expressed in this presentation are those of the presenter and do not necessarily
constitute the opinions or recommendations of Ipsen (i.e. The scientific information may
include data/information on drugs that have not yet received price and reimbursement
approval by local regulatory authorities). CBZ-ALL-002167/CBZ-BE-000412
Date of preparation: August 2020
18.20 - 19.20 INCYTE INDUSTRY PARTNER SYMPOSIUM
Personalised Approaches in Cholangiocarcinoma
What is the best way to navigate the genomic diversity of cholangiocarcinoma? How do
clinicians ensure patients with cholangiocarcinoma receive the most appropriate treatment
tailored to their individual needs?
These are the key questions addressed by four leading cholangiocarcinoma experts, as they
share experiences and practical guidance on a precision medicine-based approach during
this educational symposium.
• Cholangiocarcinoma: Not a single disease
• Cholangiocarcinoma molecular characterisation: Challenges and opportunities
• Cholangiocarcinoma clinical research: What’s new?
Speakers:
Bruno Sangro, Director of the Liver Unit and Co-Director of the HPB Oncology Area Clínica
Universidad de Navarra
Dr. Harpreet Wasan, London, UK
Dr. Ana Vivancos, Barcelona, Spain
Dr. Joachim Mertens, Zurich, Switzerland
19 I ILCA VIRTUAL CONFERENCE 2020Symposia
Partner Symposia
SATURDAY, 12TH SEPTEMBER 2020
14.00 - 15.00 EISAI INDUSTRY PARTNER SYMPOSIUM
The evolving HCC treatment landscape: what is the role of LENVIMA®
monotherapy in first-line uHCC?
In this symposium, Professor Andrew Zhu and Professor Arndt Vogel will discuss the role of
LENVIMA® monotherapy in the rapidly evolving uHCC treatment landscape. This will include
discussions around patient selection and clinical considerations in the first line setting as
well as an overview of the latest clinical data for LENVIMA® monotherapy.
• The role of LENVIMA® monotherapy in first-line uHCC
• What did we learn when results for REFLECT were released?
• What have we learnt following REFLECT?
Speakers:
Professor Andrew Zhu, Professor of Medicine at Harvard Medical School and Director
Emeritus of Liver Cancer Research at Massachusetts General Hospital and Director, Jiahui
International Cancer Center, Shanghai, China
Professor Arndt Vogel, Professor for gastrointestinal oncology at the Hannover Medical
School
The materials for LENVIMA® produced by Eisai for this virtual conference are approved for
UK healthcare professionals and other relevant decisions makers. LENVIMA® is indicated in
the UK as monotherapy for the treatment of adult patients with advanced or unresectable
hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
For the full UK prescribing information, go to the following link: eisaihcc.com. Prescribing
information may vary depending on local approval for each country. Therefore, before
prescribing any product, always refer to local materials such as the prescribing information
and/or the Summary of Prescribing Characteristics (SPC).
Adverse events should be reported. Reporting forms and information can be found at https://
yellowcard.mhra.gov.uk/ or search for the MHRA Yellow Card in the Google Play or Apple
App Store, or Ireland: www.hpra.ie. Adverse events should also be reported to Eisai Ltd on
+44 (0)845 676 1400/ +44 (0)208 600 1400 or EUmedinfo@eisai.net
20 I ILCA VIRTUAL CONFERENCE 2020Symposia
Partner Symposia
SUNDAY, 13TH SEPTEMBER 2020
14.00 - 15.00 BOSTON SCIENTIFIC INDUSTRY PARTNER SYMPOSIUM
Y90: A Step Towards Curative Therapies for HCC
Join Boston Scientific symposium to learn more about the 15-year, 207 patient experience
on SIRT.
• Long Term Outcomes of Liver Transplant Following Y90
• SIRT for Downstaging
• Positioning SIRT in the Treatment Algorithm
Speakers:
Dr Talia Baker, Transplant Surgeon, University of Chicago, USA
Dr Peter Littler, Interventional Radiologist, Freeman Hospital, UK
Dr Julien Edeline, Medical Oncologist, Centre Eugene Marquis, France
HCP based in France should be aware of the following statement:
Il est recommandé aux médecins basés en France de consulter les instructions suivantes:
Les informations disponibles sur la page Boston Scientific sont destinées au public
international de professionnels de santé assistant au congrès ILCA et ne sont pas
spécifiquement destinés aux professionnels de santé exerçant en France, n’étant donc pas
soumis à l’obligation de mise en conformité à la loi française relative à la publicité des
dispositifs médicaux.
Pour obtenir la documentation en français, mentions obligatoires et fiches techniques, merci
d’adresser vos demandes à aurore.besset@bsci.com Dispositifs médicaux, consultez les
notices spécifiques à chacun pour plus d’information.
▶ Index of Authors
The Index of Authors lists all abstract authors in alphabetical order. To locate the page of the abstract, first take note of
the abstract number (Example: P-002) and then locate the abstract, listed by type of presentation and in sequential order,
in the table of contents, where you will find a reference for the page number.
▶ Disclaimer
This Book of Abstracts has been produced using author-supplied copies. Editing has been restricted to minor spelling
corrections where appropriate, otherwise every effort has been made to reproduce the abstracts as originally submitted.
The organiser and publishers assume no responsibility for any injury and/or damage to persons or property as a matter
of product liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas
contained in the material herein. In view of rapid advances in medical sciences, independent verification of diagnoses and
drug doses is recommended.
21 I ILCA VIRTUAL CONFERENCE 2020▶ www.ilca2020.org ▶ www.ilca-online.org
You can also read
